This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
39
Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
Peripheral Diastolic Blood Pressure (DBP)
Peripheral diastolic blood pressure (DBP) at post-baseline (visit 13, week 18)
Time frame: 18 weeks post initiation of randomized treatment
Peripheral Systolic Blood Pressure (SBP)
Peripheral systolic blood pressure (SBP) at visit 13 (week 18)
Time frame: 18 weeks post initiation of randomized treatment
Proportion of Patients With Peripheral SBP <140 mm Hg and DBP <90 mm Hg at Week 18
Proportion of Patients with Peripheral SBP \<140 mm Hg and DBP \<90 mm Hg at Week 18
Time frame: 18 weeks post-treatment
Left Ventricular Ejection Fraction (LVEF) (%) at Week 18
Left ventricular ejection fraction (LVEF) (%) at Week 18
Time frame: 18 weeks post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Forest Investigative Site
Birmingham, Alabama, United States
Forest Investigative Site
Peoria, Arizona, United States
Forest Investigative Site
Buena Park, California, United States
Forest Investigative Site
Los Angeles, California, United States
Forest Investigative Site
Orange, California, United States
Forest Investigator Site
Santa Ana, California, United States
Forest Investigative Site
Guilford, Connecticut, United States
Forest Investigator Site
Coral Gables, Florida, United States
Forest Investigative Site
Daytona Beach, Florida, United States
Forest Investigator Site
Hollywood, Florida, United States
...and 24 more locations